ENALAPRIL ( DrugBank: Enalapril )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	1
46	悪性関節リウマチ	1
66	IgA腎症	3
113	筋ジストロフィー	2
210	単心室症	1
222	一次性ネフローゼ症候群	1

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00446862 (ClinicalTrials.gov)	March 2007	11/3/2007	The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study	Fabry Disease;Proteinuria	Drug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers	University of Alabama at Birmingham	NULL	Completed	19 Years	85 Years	Both	36	N/A	United States;Slovenia;Germany

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03667131 (ClinicalTrials.gov)	February 13, 2017	10/9/2018	Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.	Effect of Prophylactic Treatment With Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis Patients.	Rheumatoid Arthritis	Drug: Enalapril Maleate;Drug: Placebo	University of Guadalajara	NULL	Completed	18 Years	80 Years	Female	59	Phase 2	Mexico

66. IgA腎症

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-C000000380	2003/04/01	31/03/2006	The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial	The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial - ARB and IgA nephropathy	IgA nephropathy	ARB valsartan ACE-I enalapril	ARB therapeutic society of IgA nephropathy	NULL	Complete: follow-up complete	16years-old	75years-old	Male and Female	400	Phase 4	Japan
2	NCT00006137 (ClinicalTrials.gov)	May 2000	3/8/2000	Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy		IGA Glomerulonephritis	Drug: enalapril	National Center for Research Resources (NCRR)	Stanford University	Completed	13 Years	60 Years	Both	43	N/A	NULL
3	NCT00367562 (ClinicalTrials.gov)	January 1996	22/8/2006	Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy	Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy	IGA Nephropathy	Drug: ENALAPRIL VALSARTAN METHYLPREDNISONE	Hospital Britanico	NULL	Completed	21 Years	70 Years	Both	20	Phase 4	Argentina

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02432885 (ClinicalTrials.gov)	June 2009	24/3/2015	Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial	Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - Angiotensin-Converting-Enzyme (ACE) Inhibitor Therapy	Myocardial Fibrosis;Muscular Dystrophies	Drug: Enalapril	InCor Heart Institute	Federal University of Minas Gerais;University of Sao Paulo	Completed	6 Years	N/A	Both	76	Phase 3	NULL
2	EUCTR2009-009871-36-DE (EUCTR)		06/08/2009	Study within children with Duchenne Muscular Dystrophy	Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy - DMD-Kardio	Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: EnalHexal®, 5 mg INN or Proposed INN: ENALAPRIL Trade Name: EnaHexal®, 10mg INN or Proposed INN: ENALAPRIL Trade Name: MetoHEXAL® Succ ® 23,75 mg Retardtabletten INN or Proposed INN: METOPROLOL SUCCINATE Trade Name: MetoHEXAL® Succ ® 47,5 mg Retardtabletten INN or Proposed INN: METOPROLOL SUCCINATE Trade Name: MetoHEXAL® Succ ® 95 mg Retardtabletten INN or Proposed INN: METOPROLOL SUCCINATE	Friedrich- Alexander- Universität Erlangen Nürnberg	NULL	Not Recruiting			Female: no Male: yes			Germany

210. 単心室症

臨床試験数 : 51 / 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00113087 (ClinicalTrials.gov)	August 2003	3/6/2005	Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network	Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)	Heart Defects, Congenital;Heart Failure, Congestive	Drug: Enalapril;Drug: Placebo	National Heart, Lung, and Blood Institute (NHLBI)	Pediatric Heart Network	Completed	N/A	45 Days	All	230	Phase 3	United States;Canada

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04183101 (ClinicalTrials.gov)	October 1, 2020	14/11/2019	Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy	Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy	C3 Glomerulopathy;Membranoproliferative Glomerulonephritis;Complement Abnormality;Dense Deposit Disease;C3 Glomerulonephritis	Drug: Aliskiren;Drug: Enalapril	Region Skane	NULL	Recruiting	6 Years	N/A	All	30	Phase 2	Sweden

先頭へ